Trial Profile
APPLAUD: A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Cystic Fibrosis in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2022
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms APPLAUD
- Sponsors Laurent Pharmaceuticals
- 03 Nov 2022 Results published in the Laurent Pharmaceuticals Media Release.
- 03 Nov 2022 Primary endpoint has been met. (Absolute change in percent predicted forced expiratory volume in 1 second (FEV1%)), according to a Laurent Pharmaceuticals media release.
- 03 Nov 2022 According to a Laurent Pharmaceuticals media release, results from the study were presented at the North American Cystic Fibrosis Conference (NACFC) 2022.